Citigroup analyst Neena Bitritto-Garg maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $7 to $5.
Why Paratek Pharmaceuticals Stock Is Up Today
Shares of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company, are up Tuesday after the company announced that it entered into a definitive agreement to be acquired by Gurnet Point Capital and Novo
